Together, these findings suggest that retention of wild-type IDH1 in gliomas enhances clinical success of T cell-activating immunotherapy, whereas IDH1 loss impairs local anti-tumor T cell responses and leads to immunotherapy failure. The gene discussed is IDH1; the disease is glioma.